Hopp til hovedinnhold

Myositt

Sist oppdatert: Sist revidert:
Sist revidert av:
  1. Senécal JL, Raynauld JP, Troyanov Y. . Editorial: A New Classification of Adult Autoimmune Myositis. Arthritis Rheumatol 2017; May;69(5): 878-884. pmid:28382651 PubMed  
  2. Selva-O'Callaghan A, Pinal-Fernandez I, Trallero-Araguás E, Milisenda JC, Grau-Junyent JM, Mammen AL.Classification and management of adult inflammatory myopathies. Lancet Neurol 2018; Sep;17(9): 816-828. pmid:30129477 PubMed  
  3. Khadilkar SV et al. Cervicobrachial polymyositis. J Clin Neuromuscul Dis. 2014; Dec;16(2): 59-68. pmid:25415516 PubMed  
  4. Watanabe Y et al. Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy. J Neurol Neurosurg Psychiatry. 2016 Oct;87(10):1038-44. pmid:27147697 PubMed  
  5. Ramanathan S, Langguth D, Hardy TA, Garg N, Bundell C, Rojana-Udomsart A, Dale RC, Robertson T, Mammen AL, Reddel SW. Clinical course and treatment of anti-HMGCR antibody-associated necrotizing autoimmune myopathy. Neurol Neuroimmunol Neuroinflamm. 2015 Apr 2;2(3):e96 . pmid:25866831 PubMed  
  6. Alshehri A, Choksi R, Bucelli R, Pestronk A. Myopathy with anti-HMGCR antibodies: Perimysium and myofiber pathology. Neurol Neuroimmunol Neuroinflamm. 2015 Jun 4;2(4):e124 . pmid:26090508 PubMed  
  7. Kassardjian CD, Lennon VA, Alfugham NB, Mahler M, Milone M. Clinical Features and Treatment Outcomes of Necrotizing Autoimmune Myopathy. JAMA Neurol. 2015 Sep 1;72(9):996-1003 . pmid:26192196 PubMed  
  8. Lim J, Rietveld A, De Bleecker JL, Badrising UA, Saris CGJ, van der Kooi AJ, de Visser M. Seronegative patients form a distinctive subgroup of immune-mediated necrotizing myopathy.. Neurol Neuroimmunol Neuroinflamm 2019. pmid:30345336 F
  9. Mammen AL. Statin-Associated Autoimmune Myopathy. N Engl J Med. 2016 Feb 18;374(7):664-9. pmid:26886523 PubMed  
  10. Ljøstad U, Mygland Å. Autoimmune myopathy associated with statin use. Tidsskr Nor Laegeforen. 2016 Sep 13;136(16):1360-2. pmid:27637055 PubMed  
  11. Naddaf E. Inclusion body myositis: Update on the diagnostic and therapeutic landscape. Front Neurol. 2022 Sep 27;13:1020113. doi: 10.3389/fneur.2022.1020113. PMID: 36237625;
  12. Wong VT, So H, Lam TT, Yip RM. Myositis-specific autoantibodies and their clinical associations in idiopathic inflammatory myopathies. Acta Neurol Scand 2020. pmid:32762037 PubMed  
  13. Gallay L, Petiot P. Sporadic inclusion-body myositis: Recent advances and the state of the art in 2016. Rev Neurol (Paris). 2016 Oct;172(10):581-586. pmid:27616487 PubMed  
  14. Greenberg SA. Pathogenesis and therapy of inclusion body. Curr Opin Neurol 2012; 25(5): 630-9. pmid:22941263 PubMed  
  15. Shelly S, Mielke MM, Mandrekar J, Milone M, Ernste FC, Naddaf E, Liewluck T. Epidemiology and Natural History of Inclusion Body Myositis: A 40-Year Population-Based Study. Neurology. 2021 May 25;96(21):e2653-e2661. PMID: 33879596. PubMed  
  16. Cummins G, O'Donovan D, Molyneux A, Stacpoole S. Facial diplegia as the presenting symptom of inclusion body myositis. Muscle Nerve. 2019 Aug;60(2):E14-E16. PMID: 31095754 PubMed  
  17. Dobloug GC, Antal EA, Sveberg L, Garen T, Bitter H, Stjärne J, Grøvle L, Gran JT, Molberg Ø. High prevalence of inclusion body myositis in Norway; a population-based clinical epidemiology study. Eur J Neurol 2015; 22: 672-e41. pmid:25530508 PubMed  
  18. Machado PM1, Dimachkie MM, Barohn RJ. Sporadic inclusion body myositis: new insights and potential therapy. Curr Opin Neurol. 2014; Oct;27(5): 591-8. pmid:25159931 PubMed  
  19. Kazamel M, Sorenson EJ, Milone M. Clinical and Electrophysiological Findings in Hereditary Inclusion Body Myopathy Compared With Sporadic Inclusion Body Myositis. J Clin Neuromuscul Dis. 2016 Jun;17(4):190-6 . pmid:27224433 PubMed  
  20. Jafri L, Sajjad A, Saleem S, Jameel H, Kanwar D. Steroid-Responsive Myositis Associated With Acute Hepatitis E Infection. Cureus. 2021 Jun 7;13(6):e15492. PMID: 34268024 PubMed  
  21. Benveniste O1, Stenzel W, Allenbach Y. Advances in serological diagnostics of inflammatory myopathies. Curr Opin Neurol. 2016 Oct;29(5):662-73. pmid: 27538058 PubMed  
  22. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003; 362: 971-82. PMID: 14511932 PubMed  
  23. Rietveld A, Lim J, de Visser M, van Engelen B, Pruijn G, Benveniste O, van der Kooi A, Saris C. Autoantibody testing in idiopathic inflammatory myopathies. Pract Neurol. 2019 Aug;19(4):284-294. PMID: 30826741 PubMed  
  24. Nicolau S, Milone M, Tracy JA, Mills JR, Triplett JD, Liewluck T. Immune-mediated necrotizing myopathy: Unusual presentations of a treatable disease. Muscle Nerve. 2021 Dec;64(6):734-739. PMID: 34617293. PubMed  
  25. Brady S, Squier W, Hilton-Jones D. Clinical assessment determines the diagnosis of inclusion body myositis independently of pathological features.J Neurol Neurosurg Psychiatry. 2013 Nov;84(11):1240-6. doi: 10.1136/jnnp-2013-305690. Epub 2013 Jul 16.PMID: 23864699 PubMed  
  26. Faruch M, Garcia AI, Del Amo M, Pomes J, Isern J, González SP, Grau JM, Milisenda JC, Tomas X. Diffusion-weighted magnetic resonance imaging is useful for assessing inflammatory myopathies. Muscle Nerve. 2019 May;59(5):555-560. PMID: 30697788 PubMed  
  27. Tasca G, Monforte M, De Fino C, Kley RA, Ricci E, Mirabella M. MRI pattern recognition in sporadic Inclusion Body Myositis. Muscle Nerve 2015. pmid:25808807 PubMed  
  28. Karvelas KR, et al. Assessing the accuracy of neuromuscular ultrasound for inclusion body myositis. Muscle Nerve. 2019; Apr;59(4): 478-481.. pmid: 30635914 PubMed  
  29. Clark KEN, Isenberg DA. A review of inflammatory idiopathic myopathy focusing on polymyositis. Eur J Neurol. 2017 Aug 17 . pmid:28816394 PubMed  
  30. Allenbach Y, et al. High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody. Brain. 2016 Aug;139(Pt 8):2131-5 . pmid:27086869 PubMed  
  31. Schmidt J. Current Classification and Management of Inflammatory Myopathies. J Neuromuscul Dis. 2018;5(2):109-129. PMID: 29865091 PubMed  
  32. Van Thillo A, Vulsteke JB, Van Assche D, Verschueren P, De Langhe E. Physical therapy in adult inflammatory myopathy patients: a systematic review. Clin Rheumatol. 2019 Aug;38(8):2039-2051. PMID: 31115788 PubMed  
  33. Talotta R, Porrello I, Restuccia R, Magaudda L. Physical activity in idiopathic inflammatory myopathies: two intervention proposals based on literature review. Clin Rheumatol. 2021 Oct 19. PMID: 34665346. PubMed  
  34. Selva-O'Callaghan A, Alvarado-Cardenas M, Pinal-Fernández I, Trallero-Araguás E, Milisenda JC, Martínez MÁ, Marín A, Labrador-Horrillo M, Juárez C, Grau-Junyent JM. Statin-induced myalgia and myositis: an update on pathogenesis and clinical recommendations. Expert Rev Clin Immunol. 2018 Mar;14(3):215-224. PMID: 29473763 PubMed  
  35. Weeding E, Tiniakou E. Therapeutic management of immune-mediated necrotizing myositis. Curr Treatm Opt Rheumatol. 2021 Jun;7(2):150-160. PMID: 34422547 PubMed  
  36. Dalakas MC. Inflammatory muscle diseases. N Engl J Med 2015; 372: 1734-47. pmid:25923553 PubMed  
  37. Khoo T, Limaye V. Biologic therapy in the idiopathic inflammatory myopathies. . Rheumatol Int 2020. pmid:31680207 PubMed  
  38. Schrey A, Airas L, Jokela M, Pulkkinen J. Botulinum toxin alleviates dysphagia of patients with inclusion body myositis. J Neurol Sci. 2017 Sep 15;380:142-147 . pmid: 28870555 PubMed  
  39. Rose MR, Jones K, Leong K, Walter MC, Miller J, Dalakas MC, Brassington R, Griggs R. Treatment for inclusion body myositis. Cochrane Database Syst Rev. 2015 Jun 30;6:CD001555 . pmid:26125437 PubMed  
  40. Amato AA, Hanna MG, Machado PM, Badrising UA, Chinoy H, Benveniste O, Karanam AK, Wu M, Tankó LB, Schubert-Tennigkeit AA, Papanicolaou DA, Lloyd TE, Needham M, Liang C, Reardon KA, de Visser M, Ascherman DP, Barohn RJ, Dimachkie MM, Miller JAL, Kissel JT, Oskarsson B, Joyce NC, Van den Bergh P, Baets J, De Bleecker JL, Karam C, David WS, Mirabella M, Nations SP, Jung HH, Pegoraro E, Maggi L, Rodolico C, Filosto M, Shaibani AI, Sivakumar K, Goyal NA, Mori-Yoshimura M, Yamashita S, Suzuki N, Aoki M, Katsuno M, Morihata H, Murata K, Nodera H, Nishino I, Romano CD, Williams VSL, Vissing J, Zhang Auberson L; RESILIENT Study Extension Group. Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis: Long-term Extension of RESILIENT. Neurology. 2021 Mar 23;96(12):e1595-e1607. PMID: 33597289 PubMed  
  41. Amato AA, et al. Treatment of sporadic inclusion body myositis with bimagrumab. Neurology. 2014; Dec 9;83(24: 2239-46. pmid:25381300 PubMed  
  42. Quinn C, Karam C. Clinical reasoning: a 39-year-old woman with progressive proximal weakness. Neurology. 2013 Jul 23;81(4):400-2. PMID: 23877797 PubMed  
  43. Mammen AL, Casciola-Rosen L, Christopher-Stine L, Lloyd TE, Wagner KR. Myositis-specific autoantibodies are specific for myositis compared to genetic muscle disease. Neurol Neuroimmunol Neuroinflamm. 2015 Nov 19;2(6):e172. . pmid:26668818 PubMed  
  44. Mohassel P, Mammen AL. Statin-associated autoimmune myopathy and anti-HMGCR autoantibodies.Muscle Nerve. 2013 Oct;48(4):477-83. doi: 10.1002/mus.23854. Epub 2013 Aug 30.PMID: 23519993 PubMed  
  45. Mygland Å, Ljøstad U, Krossnes BK. Persisting weakness after withdrawal of a statin. BMJ Case Rep 2014. pmid:24713712 PubMed  
  46. Mariampillai K, Granger B, Amelin D, Guiguet M, Hachulla E, Maurier F, Meyer A, Tohmé A, Charuel JL, Musset L, Allenbach Y, Benveniste O.. Development of a New Classification System for Idiopathic Inflammatory Myopathies Based on Clinical Manifestations and Myositis-Specific Autoantibodies.. JAMA Neurol. 2018. pmid:30208379 PubMed  
  • Unn Ljøstad, spesialist i nevrologi, professor PhD
  • Åse Mygland, spesialist i nevologi, professor dr med